Date
|
Update
|
08 March 2024
|
Invitation to participate |
11 December 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and it is now anticipated to begin in early March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
27 October 2023 - 20 November 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
20 October 2023
|
Following a request received from the company, NICE will be undertaking an evaluation of Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]. The evaluation is expected to start during early-October 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during late-November 2023. |
20 October 2023
|
In progress |